Silence Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Silence Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP establishes pipeline identity, ownership and stage, reconstructs transaction precedent and retrieves financial-report signals; Current Awareness MCP checks recent events. Explore the MCP servers used in this report.
Decision date: 17 July 2026. This is a screening memorandum, not legal, medical, patent or investment advice. Pipeline and deal records change; confirm all material facts in primary documents.
Executive BD thesis
Silence Therapeutics presents a focused partnering screen across siRNA therapeutics, cardiovascular disease and hematology. PatSnap organization_pipeline_fetch returned 38 organization-linked records. This count is a discovery universe, not a count of active proprietary programs: duplicates, combination records, regional rights, investigator work and discontinued entries can be present. The decision question is therefore not “How large is the pipeline?” but “Which named assets have a credible owner, evidence package, rights path and partner-shaped execution gap?”
The near-term thesis is to prioritize assets where a partner can add measurable value through territory access, clinical development, biomarkers, combination strategy, manufacturing, delivery or commercialization. The shortlist below favors interpretable stage and target evidence, while flagging the IP and ownership work that must precede a term sheet.
1. Pipeline heat map and portfolio implications
The visible pipeline is concentrated in siRNA therapeutics, cardiovascular disease and hematology. Approved or registrational programs may support lifecycle, formulation, evidence-generation and geographic expansion transactions. Phase 2-3 programs can support co-development, co-funding and regional licensing. Earlier programs should be approached through options or staged research collaborations that defer valuation until target engagement, safety and translational evidence are available.
- Commercial/lifecycle layer: look for new indications, combinations, delivery improvements and underpenetrated regions.
- Late-development layer: test whether an external partner can shorten enrollment, supply, diagnostics or regulatory timelines.
- Innovation layer: focus on modality or biology differentiation, not pipeline labels alone.
- White-space layer: identify where the company has scientific intent but lacks a visible enabling asset, platform or regional footprint.
2. Prioritized partnering shortlist
| Priority | Owner | Asset / target | Stage | Indication signal | Evidence package to request | IP-risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|---|
| 1 | Silence Therapeutics | Zerlasiran Lp(a) | Phase 3 / Phase 2 / Phase 1 | Cardiovascular disease; atherosclerosis | Clinical and regulatory package; mechanism rationale; CMC readiness; territory-specific commercial evidence. | Composition, platform, target, biomarker and method-of-treatment claims; assess FTO and encumbrances. | Hansoh elected not to continue development under a three-target siRNA collaboration | Lead with lifecycle, geographic expansion or evidence-generation value. |
| 2 | Silence Therapeutics | Divesiran TMPRSS6 | Phase 2 / Phase 1 | Polycythemia vera; beta-thalassemia | Clinical and regulatory package; mechanism rationale; CMC readiness; territory-specific commercial evidence. | Composition, platform, target, biomarker and method-of-treatment claims; assess FTO and encumbrances. | A Mallinckrodt collaboration ended while a cardiovascular Phase 2 signal advanced | Offer development acceleration, biomarker, combination or regional commercialization capabilities. |
| 3 | Silence Therapeutics | SLN-312 ANGPTL3 | Phase 1 | Cardiometabolic / neurologic indication signal | Clinical and regulatory package; mechanism rationale; CMC readiness; territory-specific commercial evidence. | Composition, platform, target, biomarker and method-of-treatment claims; assess FTO and encumbrances. | Gubra concluded a research agreement with Silence | Propose an option, co-development or platform structure with staged diligence gates. |
How to read the shortlist: “Owner” is the organization linked in the pipeline record and still requires legal-chain confirmation. “Stage” reflects the returned status footprint, which can differ by indication and geography. The evidence package is the minimum diligence bundle for a BD conversation. IP-risk language is a triage flag only; it is not a patentability or freedom-to-operate opinion.
3. Transaction precedent
drug_deal_search returned 2 licensee-side and 5 licensor-side records under the company-name searches used for this scan. Search totals can include affiliates, duplicate summaries and transactions outside the proposed asset scope, so full records must be fetched and normalized before using headline economics as comparables.
| Date | Observed precedent | BD implication |
|---|---|---|
| 2025-02-27 | Hansoh elected not to continue development under a three-target siRNA collaboration | Confirm rights, economics, diligence scope and current status in the full deal record. |
| 2024-03-13 | A Mallinckrodt collaboration ended while a cardiovascular Phase 2 signal advanced | Confirm rights, economics, diligence scope and current status in the full deal record. |
| 2022-02-10 | Gubra concluded a research agreement with Silence | Confirm rights, economics, diligence scope and current status in the full deal record. |
The precedent pattern helps determine acceptable structures: global or regional licenses, research collaborations, options, co-development, acquisition, royalty financing, supply arrangements or commercialization partnerships. It does not establish that any shortlisted asset is available. Outreach should reference one relevant precedent, then explain why the proposed contribution differs in territory, evidence, technology or capital intensity.
4. Financial and strategic capacity signal
financial_report_search returned no clearly attributable financial-report match in this run. Obtain the newest filed statements directly before assessing cash capacity, obligations or transaction urgency.
For transaction design, reconcile cash and equivalents, operating cash flow, debt, collaboration revenue, R&D commitments, launch investment, contingent consideration and milestone obligations. A company can be scientifically active but constrained in a specific geography or program; conversely, strong liquidity does not eliminate the need for an enabling partner. Use the latest filing and earnings materials before assigning capacity or urgency.
5. Current-awareness layer
news_search was run for company, pipeline, licensing, partnership and milestone concepts. No clearly attributable result was returned in the top semantic matches for this run. An empty result is not evidence of no activity. Refresh the search immediately before outreach and verify events against company releases, regulatory notices and trial registries.
6. IP, ownership and diligence gates
- Ownership: confirm parent/subsidiary identity, inventorship, assignments, prior licenses, options, liens and change-of-control provisions.
- Patent scope: map composition, sequence, platform, target, formulation, process, dosing, combination and method-of-treatment families by jurisdiction.
- FTO: screen third-party blocking rights, research-tool licenses, manufacturing dependencies and geographic carve-outs.
- Evidence: obtain protocols, statistical plans, readouts, safety narratives, regulatory correspondence, CMC comparability and raw translational support.
- Economics: model risk-adjusted value by indication and territory, including milestones, royalties, cost sharing, supply and tax.
7. Outreach plan
- Map the asset team, therapeutic-area BD lead, regional commercial lead and alliance-management owner.
- Lead with one quantified gap: enrollment, evidence, diagnostics, manufacturing, delivery, combination strategy or territory access.
- Attach a one-page evidence matrix covering stage, indication, partner contribution, decision gates and proposed structure.
- Offer two structures, such as regional license versus option-to-license, with clear diligence and governance paths.
- Request a focused data room and agree on ownership, IP/FTO, CMC, safety, regulatory and economics workstreams.
8. Decision memo
ADVANCE TARGETED OUTREACH. The selected programs have identifiable partner-shaped rationales, and the observed transaction history supports a structured conversation. Tailor first contact to a named asset, indication and territory; quantify the contribution; and acknowledge the main IP, evidence and execution risks. Do not use pipeline size as a substitute for fit.
Required next diligence: refresh pipeline and Current Awareness searches; retrieve full deal records; reconcile the newest financial filing; verify owner and license chain; complete patent-family and FTO work; and model risk-adjusted economics.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow
Data provenance: PatSnap Company & Deal Intelligence MCP (organization_pipeline_fetch, drug_deal_search, financial_report_search) and Current Awareness MCP (news_search); accessed 17 July 2026.
